Long QT syndrome (LQTS) is characterized by prolongation of the QT
interval on the electrocardiogram (ECG). Clinically, LQTS is associated
with the development of Torsades de Pointes (TdP), a well-defined
polymorphic ventricular tachycardia and the development of sudden
cardiac death (1). The most common type is the acquired form caused
mainly by drugs, it is also known as the drug induced LQTS (diLQTS)
(2-5). The diLQTS is caused by certain families of drugs which can
markedly prolong the QT interval on the ECG most notably antiarrhythmic
drugs (class IA, class III), anti-histamines, antipsychotics,
antidepressants, antibiotics, antimalarial, and antifungals (2-5). Some
of these agents including the antimalarial drug hydroxycholoquine and
the antibiotic azithromycin which are being used in some countries as
therapies for the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2)(6,7). However, these drugs have been implicated in causing
prolongation of the QT interval on the ECG (2-5).There is a solution for
monitoring this large number of patients which consists of using mobile
ECG devices instead of using the standard 12-lead ECG owing to the
difficulty of using the 12-lead ECG due to its medical cost and
increased risk of transmitting infection. These mobile ECG devices have
been shown to be effective in interpreting the QT interval in patients
who are using QT interval prolonging drugs (8, 9). However, the ECG
mobile devices have been associated with decreased accuracy to interpret
the QT interval at high heart rates (9). On the other hand, some of them
have been linked with no accuracy to interpret the QT interval (10).
This can put some patients at risk of TdP and sudden cardiac death.
In this current issue of the Journal of Cardiovascular
electrophysiology, Krisai P et al. reported that the limb leads
underestimated the occurrence of diLQTS and subsequent TdP compared to
the chest leads in the ECG device, this occurred in particular with the
usage of mobile standard ECG devices which use limb leads only. To
illuminate these findings, the authors have studied the ECGs of 84
patients who have met the requirements for this study, which are diLQTS
and subsequent TdP. Furthermore, the patients in this study were also
taking a QT interval prolonging drug. Krisai P et al. additionally
reported the morphology of the T-wave in every ECG and classified them
into flat, broad, notched, late peaked, biphasic and inverted. The
authors showed that in 11.9% of these patients the ECG was non reliable
in diagnosing diLQTS and subsequent Tdp using only limb leads due to
T-wave flattening in these leads, in contrast to chest leads where the
non- interpretability of the QT interval was never attributable to the
T-wave morphology but to other causes. The authors further examined the
QT interval duration in limb leads and chest leads and found that the QT
interval in limb leads was shorter compared to that of the chest leads,
but reported a high variability in these differences. Therefore, it
should be taken into account when screening patients with diLQTS using
only mobile ECG devices and these patients should be screened using both
limb leads and chest leads. Moreover, the authors have highlighted the
limitations of using ECG mobile devices as limb leads to interpret the
QT interval especially in high heart rates (when Bazett’s equation
overcorrects the QTc and overestimates the prevalence of the QT
interval) and have advocated the usage of ECG mobile devices as chest
leads instead of limb leads due to their superior ability to interpret
the QT interval.
The authors should be praised for their efforts in illustrating the
difference in the QT interval interpretability between the chest leads
and the limb leads in patients with diLQTS. The authors also pointed out
the limitation of using mobile ECG devices as limb leads for the
diagnosis of diLQTS and recommended their usage as chest leads by
applying their leads onto the chest due to their better diagnostic
accuracy for detecting the diLQTS. The study results are very relevant,
it further expanded the contemporary knowledge about the limitation of
the QT interval interpretability using ECG mobile device only (11).
Future investigation is needed to elucidate the difference in chest and
limb leads interpretability of the QT interval and to assess the ability
of the mobile ECG devices to interpret the QT interval.
References
- Refaat MM, Hotait M, Tseng ZH: Utility of the Exercise
Electrocardiogram Testing in Sudden Cardiac Death Risk Stratification.
Ann Noninvasive Electrocardiol 2014; 19(4): 311-318.
- Kannankeril P, Roden D, Darbar D. Drug-Induced Long QT Syndrome.
Pharmacological Reviews. 2010;62(4):760-781.
- Nachimuthu S, Assar M, Schussler J. Drug-induced QT interval
prolongation: mechanisms and clinical management. Therapeutic Advances
in Drug Safety. 2012;3(5):241-253.
- Jankelson L, Karam G, Becker M, Chinitz L, Tsai M. QT prolongation,
torsades de pointes, and sudden death with short courses of
chloroquine or hydroxychloroquine as used in COVID-19: A systematic
review. Heart Rhythm. 2020 ; S1547-5271(20)30431-8.
- Li M, Ramos LG. Drug-Induced QT Prolongation And Torsades de
Pointes. P T . 2017;42(7):473-477.
- Singh A, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and
hydroxychloroquine in the treatment of COVID-19 with or without
diabetes: A systematic search and a narrative review with a special
reference to India and other developing countries. Diabetes &
Metabolic Syndrome: Clinical Research & Reviews. 2020;14(3):241-246.
- Hashem A, Alghamdi B, Algaissi A, Alshehri F, Bukhari A, Alfaleh M et
al. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19
and other viral infections: A narrative review. Travel Medicine and
Infectious Disease. 2020; 35:101735.
- Chung E, Guise K. QTC intervals can be assessed with the AliveCor
heart monitor in patients on dofetilide for atrial fibrillation. J
Electrocardiol. 2015;48(1):8-9.
- Garabelli P, Stavrakis S, Albert M et al. Comparison of QT Interval
Readings in Normal Sinus Rhythm Between a Smartphone Heart Monitor and
a 12-Lead ECG for Healthy Volunteers and Inpatients Receiving Sotalol
or Dofetilide. Journal Cardiovasc Electrophysiol. 2016;27(7):827-832.
- Bekker C, Noordergraaf F, Teerenstra S, Pop G, Bemt B. Diagnostic
accuracy of a single‐lead portable ECG device for measuring QTc
prolongation. Annals Noninvasive Electrocardiol. 2019;25(1): e12683.
- Malone D, Gallo T, Beck J, Clark D. Feasibility of measuring QT
intervals with a portable device. American Journal of Health-System
Pharmacy. 2017;74(22):1850-1851.